Ozempic and GLP-1 lawsuits: 4,025 injury cases are pending in federal court

The plaintiffs allege that these GLP-1 drugs caused gastroparesis and other gastrointestinal injuries, and that the makers failed to warn about them.

Both defendant groups deny the allegations. The JPML counted 4,025 pending actions as of October 1, 2026.

The court held a Rule 702 (Daubert) hearing on expert evidence from September 14 to 18, 2026. No court has found the makers liable.

The plaintiffs allege that Ozempic, Wegovy, Saxenda and Trulicity caused non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of vision in one eye.

The JPML centralized the cases in Philadelphia on December 15, 2025, before the same judge as the stomach-injury MDL, and counted 247 pending actions as of October 1, 2026.

These are allegations, not findings.

Novo Nordisk has filed 130+ lawsuits against compounding pharmacies selling compounded semaglutide, alleging patent infringement and patient safety violations.

Many resulted in settlements or pharmacy closures.

Eli Lilly is pursuing similar patent enforcement actions against pharmacies compounding tirzepatide (the active ingredient in Mounjaro/Zepbound).

FDA had listed tirzepatide as in shortage since December 2022 and determined that shortage resolved on December 19, 2024, and it was that resolution, not a finding that the shortage never existed, that ended the broad compounding window.

On July 29, 2026 the Federal Trade Commission, joined by the Utah Division of Consumer Protection and the People of the State of California acting through Los Angeles County Counsel Dawyn R. Harrison, filed a Complaint for Permanent Injunction, Monetary Judgment, Civil Penalty Judgment, and Other Relief against Hims & Hers Health, Inc. The complaint alleges the company fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling them they will be able to consult a medical provider first; that it made subscriptions difficult to cancel; and that it shared consumers' health information with Meta, Snap and other third parties despite claiming its services keep that information private.

Case status is Pending. These are allegations that have not been proven in court, and the company has not been found liable.

Hims and Hers are the two consumer brands of this defendant, and both of our review pages carry the same disclosure.

The FTC is investigating multiple telehealth companies for deceptive marketing practices related to GLP-1 medications, including false efficacy claims, hidden pricing, and misleading before/after imagery.

State attorneys general in Texas, California, Florida, and 9+ other states are pursuing enforcement against companies selling compounded GLP-1 medications without proper licensing or making unsubstantiated health claims.